Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30695802 | 1.00 | CYP11B1 (0.51) | CYP11B1CYP11B2BRD4CMA1AHR | |
| SCHEMBL3597266 | 0.79 | LMNA (0.51) | CYP11B1CYP11B2PDE3BPDE3AKCNH2 | |
| SCHEMBL3597262 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2AHRPDE3BPDE3A | |
| SCHEMBL3068531 | 0.79 | AHR (0.56) | CYP11B1CYP11B2CMA1AHRTGM2 | |
| SCHEMBL10916724 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2BRD4AHRPDE3B | |
| SCHEMBL13692913 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2AHRTDP2TGM2 | |
| SCHEMBL434348 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2BRD4PDE3BPDE3A | |
| SCHEMBL31261247 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2PDE3BPDE3APARP10 | |
| SCHEMBL4170386 | 0.75 | CYP11B1 (0.48) | CYP11B1CYP11B2AHRPDE3BPDE3A | |
| SCHEMBL2056370 | 0.75 | PARP1 (0.51) | CYP11B1CYP11B2PDE3BPDE3APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696688-A1 | BENZO-FUSED RING COMPOUND INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4624464-A1 | PYRIDINE POLYCYCLIC COMPOUND INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025021062-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| WO-2024222814-A1 | CYP11B2 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-10-31 | — | — | WO | disclosed |
| WO-2024213042-A1 | BENZO-FUSED RING COMPOUND INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-10-17 | — | — | WO | disclosed |
| US-20240208953-A1 | \"Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B\ | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024109885-A1 | PYRIDINE POLYCYCLIC COMPOUND INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-05-30 | — | — | WO | disclosed |
| EP-4313041-A1 | NOVEL CYCLOPENTAL[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157072-A | Novel cyclopento [ c ] pyrrole NR2B negative allosteric modulators | 诺华股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
| EP-2464632-A1 | PYRIMIDONE DERIVATIVES USED AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20120071471-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2012-03-22 | — | — | US | disclosed |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-12 | — | — | US | disclosed |
| EP-2280954-A1 | 6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2 | Universität des Saarlandes (DE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2010103064-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-09-16 | — | — | WO | disclosed |
| WO-2009135651-A1 | 6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2 | UNIVERSITÄT SAARLANDES (DE) | 2009-11-12 | — | — | WO | disclosed |
| US-7442696-B2 | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | LIGAND PHARMACEUTICALS INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2006010142-A2 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208953-A1 | \"Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B\ | GRIN2C, GRIN2B, GRIN2A | CYP11B1 943/4885CYP11B2 756/4885BRD4 1860/4885 |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | HSD11B1, HSD11B2, CYP4A11 | CYP11B1 6/4885CYP11B2 4/4885BRD4 1721/4885 |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | HSD11B1, HSD11B2, CYP11B1 | CYP11B1 3/4885CYP11B2 4/4885BRD4 4059/4885 |
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | NR3C2, MC2R, NR3C1 | CYP11B1 12/4885CYP11B2 7/4885BRD4 968/4885 |
| US-20120071471-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | PMP22, GRIN2C, NLN | CYP11B1 159/4885CYP11B2 141/4885BRD4 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.